UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Jun

    10

    Nicole Watson: Mom, Caregiver, and Best Friend, Shares How Her Daughter Emma, Diagnosed with Dravet Syndrome, Embraces Each Day with Love

    May

    10

    Moms Really Can Do It All - Meet Tracy: a Mom, Caregiver, Neuroscientist, and Advocate in the Rare Disease Community

    Mar

    19

    Patty Fritz and Bianca Anderson Recognized by the Healthcare Businesswomen’s Association (HBA) as UCB Luminary and Rising Star

    Mar

    09

    First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

    Mar

    06

    Putting People First to Create a More Sustainable Healthcare System

    Feb

    28

    UCB on Growth Path for a Decade Plus

    Jan

    03

    ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

    Dec

    02

    UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

    Dec

    01

    Media Statement on levetiracetam (KEPPRA® and KEPPRA XR®) and DRESS

    Nov

    17

    Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate